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Edited by Lukas HuberAbstract TPA, a potent PKC activator, inhibits myogenic
diﬀerentiation and activates phospholipase D (PLD). We eval-
uated the involvement of PLD in the TPA eﬀects on L6
myoblasts diﬀerentiation. TPA, at concentrations inhibiting
diﬀerentiation of L6 cells, induced a strong, though transient,
PLD activation. Surprisingly, at nanomolar concentration, TPA
induced both myogenic diﬀerentiation and sustained activation of
PLD. Diﬀerential eﬀect of TPA can be ascribed to PKC
downregulation induced by highest TPA concentrations. TPA-
induced diﬀerentiation was inhibited by 1-butanol, conﬁrming the
involvement of PLD in this eﬀect. These data suggest that
prolonged elevation of PLD activity is required for myogenic
diﬀerentiation.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Myogenic diﬀerentiation is a complex process which consists
in the conversion of proliferating skeletal myoblasts into
polynucleated myotubes expressing the contractile apparatus
[1]. Diﬀerent signaling pathways are involved, including the
activation of PKC [2], RhoA [3], PI3K/Akt [4], and p38
MAPkinase [5]. The studies aiming at delineating the role of
PKCs in myogenesis have led to conﬂicting conclusions, due to
the multiplicity of the isoenzymes involved, and to the bimodal
eﬀects of phorbol ester treatments, which both activate and
downregulate the responsive PKCs [6–12]. In view of reported
data showing that phospholipase D (PLD) is activated by
phorbol esters in L6 cells [13], we asked if PKC-dependent
PLD activation was correlated with an induction of myogen-
esis. A possible involvement of the PLD pathway of signaling* Corresponding author. Fax: +33-4-72-43-85-24.
E-mail address: georges.nemoz@insa-lyon.fr (G. Nemoz).
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Abbreviations: TPA, 12-O-Tetradecanoylphorbol 13-acetate; AVP,
Arg8-vasopressin; PLD, phospholipase D; PKC, protein kinase C
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doi:10.1016/j.febslet.2004.10.036in myogenesis had been suggested by our previous observation
that in vitro diﬀerentiation of L6 myoblasts can be induced by
the hormone arginin8-vasopressin (AVP) in the absence of
serum or other factors, when present at concentrations which
trigger a rapid activation of PLD, without a concomitant ac-
tivation of phospholipase C [14]. PLD and its product phos-
phatidic acid have been shown to be involved in the regulation
of essential cellular functions, such as vesicular traﬃc and
cytoskeleton rearrangements [15], but the role of this pathway
in myogenesis has not yet been thoroughly investigated. PLD
is known to be activated through diﬀerent mechanisms, the
most prominent involving PKCs and interaction with small G
proteins of the ARF and Rho families [16]. Our observation
that phorbol esters are able to induce both PLD activation and
myogenic diﬀerentiation in the absence of physiological eﬀec-
tors suggests that PKC is positively involved in myogenesis
through PLD regulation, and supports the hypothesis that
PLD activity is required for the myogenic process.2. Materials and methods
Cell culture. L6 cells of the C5 subclone [17] were seeded at the
density of 10 000/cm2 in DMEM supplemented with 100 U/ml peni-
cillin, 100 lg/ml streptomycin, and 10% heat-inactivated FBS. 24 h
after plating, cultures were shifted to 5% FBS-containing medium,
supplemented with various concentrations of TPA. The cells were
cultured for 5 d, the medium was changed every day. Percentage of cell
fusion was measured as detailed in [17]. Myosin expression was visu-
alized by immunocytochemistry, using the MF20 antibody directed
against sarcomeric myosin (kindly given by Dr. D. Fischman, Cornell
University Medical College, New York, NY), and HRP-conjugated
secondary antibody, as described in [17]. Creatine kinase activity of the
cells was assayed as previously described [17]. Measurement of ace-
tylcholine receptor expression was performed by [125I]-a-bungarotoxin
binding, as described in [18]. Alternatively, the cells could be diﬀer-
entiated by culture in serum-free medium supplemented with 1% BSA
(Roche Applied Science), and 107 M AVP (Sigma) or TPA, and
myogenin was assessed as described below.
Myogenin immunoblotting and immunoﬂuorescence. After 48 h of
culture in BSA medium in the presence of appropriate agents, the cells
were homogenized in ice-cold 20 mM Tris/HCl, pH 7.6, containing a
protease inhibitor cocktail (Sigma P2714) diluted 1:4, in a Dounce
homogenizer (30 strokes). The homogenates were analyzed on a 15%
polyacrylamide gel and immunoblotted with F5D anti-myogenin
monoclonal antibody (Developmental Studies Hybridoma Bank,
University of Iowa, Iowa City, IA) diluted 1:50. After stripping, the
membranes were reprobed for normalization, with an anti-tubulin
monoclonal antibody (Sigma). Immunoblots were revealed with the
ECL detection system (Amersham Biosciences). Videodensitometrication of European Biochemical Societies.
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system (ImageMaster VSD-CL, Amersham Biosciences) and Image-
Quant software. Proteins were assayed by the Bradford method. Al-
ternatively, myogenin nuclear accumulation was detected by
immunoﬂuorescence, using F5D monoclonal antibody as described in
[17]. The cells were examined by ﬂuorescence microscopy, with a Zeiss
Axiovert 200 microscope, an objective LD A-plan, 20·/0.30 PHI1/40,
a Zeiss Axiocam MRm camera, and Axiovision 4.1 image acquisition
software. The total number of nuclei in the considered ﬁelds was as-
sessed on phase contrast images.
Actin labeling. The cells were kept in 1% BSA-containing medium for
3 h before being challenged by 1 nM TPA for 15 min. When required,
0.5% 1-butanol or 2-butanol was added to the culture medium 10 min
before TPA. The cells were ﬁxed by 3.7% formaldehyde for 10 min at 4
C, permeabilized with 0.1% Triton for 15 min at 4 C, and aspeciﬁc
labeling was blocked in 1% BSA for 20 min. The cells were then stained
for 5 min by rhodamine-conjugated phalloidin (Molecular Probes)
diluted 1:400, before ﬂuorescence microscopy examination.
Phospholipase D activity assay. PLD was evaluated on the basis of its
transphosphatidylation activity, by quantitating phosphatidylbutanol
accumulated in intact cells. The cells cultured in 10% FBS-containing
medium were shifted to serum-free medium and incubated for 2 h in
the presence of 2 lCi/ml of [3H]-palmitic acid (Perkin Elmer Life
Sciences). After 2 washes, the labeled cells were shifted to 1% BSA-
containing medium, and treated or not for 30 min by 107 M AVP, or
various concentrations of TPA, in the presence of 1% 1-butanol. When
required, TPA was added 24 h before labeling. PLD assay incubations
were terminated by washing with ice-cold PBS and adding 0.5 ml of 0.1
N HCl in PBS. The cells were scraped and lipids were extracted ac-
cording to [19], in the presence of 50 lM butylhydroxytoluene.
Phosphatidylbutanol was separated by bidimensional TLC on silica
gel G60 plates (Merck) using chloroform/methanol/28% ammonia
(65:35:5.5 by volume) as a solvent for the ﬁrst migration, and ethyl
acetate/isooctane/acetic acid (90:50:20 by volume) for migration in the
second dimension. Spots stained by Coomassie Brilliant Blue R were
scraped oﬀ and radioactivity was measured by liquid scintillationFig. 1. L6 myoblasts cultured in 5% FBS-containing medium fully diﬀerent
phology of cells cultured in the presence of the indicated agent was examin
marker myosin heavy chain. (B) Cell fusion was quantitated after culture with
marker creatine kinase was assayed. (D) The late diﬀerentiation marker Achcounting. The radioactivity associated with phosphatidylbutanol was
expressed in percent of total phospholipid radioactivity.
Protein kinase C immunoblotting. Cells were cultured as described,
harvested, collected by centrifugation, resuspended in ice-cold ho-
mogenization buﬀer (20 mM Tris, pH 7.5, 2 mM EDTA, 2 mM
EGTA, 250 mM sucrose, 5 mM DTT, 100 mg/ml leupeptin, 100 mg/ml
aprotinin and 3.5 mg/ml PMSF), and sonicated. Cell homogenates
were centrifuged at 100 000 · g for 30 min. The supernatant consti-
tuted the soluble fraction. The pellet was resuspended in the homog-
enization buﬀer containing 0.1% Triton X-100, incubated on ice with
repeated vortexing, and centrifuged at 15 000 · g for 15 min. The ﬁnal
supernatant is referred to as particulate fraction. The fractions were
submitted to SDS–PAGE on 10% polyacrylamide gels. The proteins
transferred on nitrocellulose sheets were probed with the PKC-
a;b1; c; i monoclonal antibodies purchased from Transduction
Laboratories. Detection was performed using the ECL technique
(Amersham). The bands were quantiﬁed as stated above. Equal protein
content of the samples was assessed by running in parallel a SDS–
polyacrylamide gel stained with Coomassie blue.3. Results
TPA is a potent activator of PLD in a number of cell sys-
tems, including L6 myoblasts [13]. To test if triggering this
pathway is accompanied by myogenic diﬀerentiation, prolif-
erating L6 myoblasts were treated by varying concentrations
of TPA, in culture conditions (5% FBS-containing medium)
which, due to intermediate serum concentration, are expected
to allow the detection of either a positive, or a negative eﬀect of
TPA on diﬀerentiation [18], and several parameters of diﬀer-
entiation were evaluated. Addition of low TPA doses (1–10
nM) eﬃciently promoted diﬀerentiation of L6 cells after 5 daysiate in the presence of nanomolar TPA concentrations. (A) The mor-
ed after immunocytochemical visualization of the late diﬀerentiation
various TPA concentrations. (C) The activity of the late diﬀerentiation
R was quantiﬁed by [125I]-a-bungarotoxin binding.
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myosin expression (Fig. 1A), and by quantiﬁcation of cell fu-
sion (Fig. 1B). By contrast, higher TPA doses (100–1000 nM)
did not promote diﬀerentiation and even inhibited the low
spontaneous rate of diﬀerentiation observed in these culture
conditions. The diﬀerential eﬀect of TPA according to the used
dose was further illustrated by quantifying the late diﬀerenti-
ation markers creatine kinase activity and a-bungarotoxin
binding (which reﬂects the number of nicotinic acetylcholine
receptors in presence) (Fig. 1C and D). In both cases, TPA at a
nanomolar range increased the expression of the marker,
whereas 100 nM or more concentrated TPA repressed it down
to below control values.
Since the above experiments showed that TPA was able to
induce diﬀerentiation, we asked whether it could act by itself,
in the absence of serum components. We thus investigated the
eﬀects of TPA on diﬀerentiation of L6 cells cultured in serum-
free, 1% BSA-containing medium. An early step in myogenic
process is the expression and nuclear accumulation of theFig. 2. L6 myoblasts cultured in the absence of serum diﬀerentiate in the
of myogenin expressed in cells cultured for 48 h in the presence of the indica
myogenin bands, as normalized by the amount of tubulin. The meanS.E
myogenin in cells cultured as above. The diagram shows the meanS.E. ofmuscle-speciﬁc transcription factor myogenin, that governs the
expression of an array of proteins typical of diﬀerentiated
myocytes [1]. Cells treated with 1 nM TPA expressed myoge-
nin, in a manner similar to cells treated by the diﬀerentiating
agent AVP taken as a positive control, which shows that they
were undergoing diﬀerentiation. By contrast, 100 nM TPA did
not induce myogenin expression (Fig. 2A). Diﬀerentiation was
further evaluated by assessment of nuclear accumulation of
myogenin by immunoﬂuorescence (Fig. 2B). These experi-
ments showed the ability of 1 nM TPA, but not of 100 nM
TPA to induce myogenin nuclear accumulation in BSA-cul-
tured cells. It can thus be concluded that TPA, at a low con-
centration, was suﬃcient by itself to trigger diﬀerentiation, in
the absence of other stimuli.
To further characterize its eﬀects on myogenesis, we inves-
tigated the consequences of TPA addition on myogenin
expression and nuclear accumulation induced by the diﬀeren-
tiating agent AVP. Whereas 1 nM TPA did not signiﬁcantly
modify either myogenin expression or nuclear accumulationpresence of 1 nM TPA, but not 100 nM TPA. (A) Immunoblotting
ted agent. The diagram shows the videodensitometric quantiﬁcation of
. of 3 independent experiments is shown. (B) Immunoﬂuorescence of
the percentages of myogenin positive nuclei as determined in 5 ﬁelds.
Fig. 3. PLD activity in TPA-treated cells. (A) Time-course of PLD
activation by 1 and 100 nM TPA. (B) PLD activity in cells activated
for 30 min by TPA and previously treated, or untreated for 24 h by
TPA. The meanS.E. of 3 or 4 independent assays is shown.
Fig. 4. Prolonged treatments by 1 and 100 nM TPA have diﬀerent
eﬀects on PKC isoform downregulation. The supernatant and mem-
brane fractions of cells treated or not (C) for 24 h by TPA at the in-
dicated concentrations were immunoblotted for diﬀerent PKC
isoforms. The observed bands were quantiﬁed by videodensitometry.
The intensity of the bands, normalized by the amount of PKCi in the
considered sample, showed signiﬁcant decreases only for the PKCa
and c isoforms, in fractions from 100 nM TPA-treated cells ()72 3%
and )91 6% for PKCa, respectively, in supernatant and pellet;
)81 4% and )55 9% for PKCc, respectively, in supernatant and
pellet, as compared to the control in the same fraction, n ¼ 3).
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suppress both responses (Fig. 2A and B), showing that at a
high concentration the phorbol ester was a diﬀerentiation
inhibitor.
In view of the well-described PLD-stimulating eﬀect of TPA,
PLD activity was evaluated in intact L6 cells treated by 1 and
100 nM TPA (Fig. 3). At the highest concentration, TPA
strongly stimulated PLD (by 14.7-fold). At 1 nM, the stimu-
lation was lower, but still marked (8.6-fold), and similar toFig. 5. 1-Butanol selectively inhibits the myogenic response to 1 nM
TPA. (A) Cells were cultured in 1% BSA medium, without addition
(control), or in the presence of 1 nM TPA, with or without 0.5%
1-butanol or 2-butanol. After 48 h, myogenin immunoﬂuorescence was
assessed. (B) The meansS.E. of the percentages of myogenin positive
nuclei counted in 10 ﬁelds were calculated. (C) Actin ﬁbers were
stained with rhodamine-phalloidin in cells kept for 15 min without
addition (control), or in the presence of 1 nM TPA, with or without
0.5% 1-butanol or 2-butanol.
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PLD activation were determined: at both TPA concentrations,
the activity reached a maximum at 30–60 min, and then pro-
gressively declined (Fig. 3A). After 24 h of treatment, PLD
activity was near starting values. Re-stimulation of the cells by
the same TPA concentration had a very diﬀerent eﬀect ac-
cording to the concentration used: after a ﬁrst treatment by 1
nM TPA, this agonist induced again a similar PLD response,
whereas stimulation of PLD was no longer observed after a
ﬁrst 100 nM TPA treatment (Fig. 3B). This shows that in the
latter conditions PLD eﬀectors were downregulated, but not
after a 24 h 1 nM TPA treatment.
The involvement of PKC in the regulation of PLD activity
being well documented and the ability of PLD to be re-stim-
ulated after a prolonged treatment with 1 nM TPA suggested
that this TPA concentration did not induce the downregula-
tion of PKC. We have thus evaluated the amounts of immu-
noreactive proteins corresponding to major PKC isoforms
present in L6 myoblasts, in both the soluble and the membrane
fractions. As shown in Fig. 4, a 24 h-treatment by 100 nM
TPA strongly lowered the PKC a and c isoform amounts in
both compartments, whereas b1 and i isoforms were not no-
tably altered. By contrast, a prolonged treatment with 1 nM
TPA did not downregulate either of the PKC isoforms.
Mammalian PLDs are characterized by their ability to
preferentially catalyze a transphosphatidylation reaction in the
presence of primary alcohols, thus producing phosphatidylal-
cohol at the expense of the normal reaction product phos-
phatidic acid. Addition of a primary alcohol such as 1-butanol
to the culture medium thus allows to straightforwardly eval-
uate the role of PLD activity in a given cell function [15]. It is
shown in Fig. 5A and B that L6 cells treated by 1 nM TPA in
the presence of 0.5% 1-butanol totally failed to accumulate
nuclear myogenin, whereas a control treatment by 0.5% 2-
butanol, an isomer which is not recognized by PLDs, had only
a moderate eﬀect. This shows that the myogenic response to 1
nM TPA required PLD activity. The role of PLD in cyto-
skeleton rearrangements being documented in some cell types,
we examined the eﬀects of 1 nM TPA treatment of L6 myo-
blasts on the organization of actin ﬁlaments. A 15 min-TPA
treatment induced the formation of stress ﬁber-like actin
structures, as evidenced by labeling with phalloidin-rhodamine
conjugate, and 1-butanol selectively inhibited this response,
showing that it depended on PLD activity (Fig. 5C).4. Discussion
This study shows a correlation between PLD stimulation
and induction of the myogenic response in L6 myoblasts,
suggesting that PLD activity is requested for the diﬀerentiation
process. Firstly, PLD was similarly activated by two diﬀerent
inducers of diﬀerentiation, AVP [14] and TPA used at a
nanomolar concentration (Fig. 3). Furthermore, the observa-
tion that the eﬀects of AVP and 1 nM TPA upon diﬀerentia-
tion were not additive suggests that the two agents acted
through the same signaling pathway. The ability of phorbol
ester to induce by itself a myogenic response at a low con-
centration is a new ﬁnding, since TPA is commonly considered
as an inhibitor of myogenesis [6,7,10–12]. However, it is in line
with data showing that chick myoblasts treated with PKC
inhibitors fail to fuse [8]. By using a number of diﬀerentiationcriteria (morphological examination, myogenin expression,
nuclear accumulation, creatine kinase activity, and nicotinic
receptor binding), we determined that 1–10 nM (but not 100–
1000 nM) TPA allowed a complete myogenic diﬀerentiation of
L6 cells, including cell fusion and expression of late markers.
This shows that activation of PKC is able to bypass the re-
quirement for a physiological eﬀector to induce both PLD
activation and myogenesis. It is noteworthy that since PLD
can also be activated through various PKC-independent
pathways [16], the involvement of other mechanisms of PLD
activation during physiologically occurring myogenesis cannot
be ruled out. Secondly, high concentrations of TPA that pre-
vented PLD from further responding to stimulation after an
initial transient activation were clearly inhibitory to the dif-
ferentiation process. The prevention of PLD-restimulation can
be attributed to the observed downregulation of PKC, and in
particular PKCa, the role of which as a regulator of the PLD1
isoform is well documented [20]. Other PKC isoforms are
downregulated by prolonged treatment of L6 myoblasts by
high doses of phorbol ester, such as PKCc (this article) and
PKCe and d, as reported in [21]. Interestingly, the PLD2 iso-
form has been shown to be activatable by PKCd-dependent
phosphorylation [22] and may thus be also aﬀected by the
elimination of TPA-sensitive PKCs. Since L6 cells express both
PLD1 and PLD2 isoforms (our unpublished results), TPA
regulation may concern the whole PLD set of these cells. The
time-courses of PLD activation in response to the initial
challenge by both high and low TPA concentrations were
similar. However, in view of the fact that a new challenge by
high TPA concentration could not re-activate PLD, it can be
deduced that periodical renewal of the 100 nM TPA-contain-
ing culture medium during the whole culture period main-
tained PLD activity at a near basal level after 24 h, whereas in
culture conditions involving nanomolar TPA, high levels of
PLD activity could be restored. It can thus be hypothesized
that maintenance of PLD under an activation-responsive state
is required for the completion of myogenic diﬀerentiation. As a
conﬁrmation of PLD involvement in the myogenic response to
nanomolar TPA, 1-butanol was able to totally suppress my-
ogenin nuclear accumulation.
PLD has been suggested to play a role in the diﬀerentiation of
several cell types, although the mechanisms of PLD participa-
tion into the diﬀerentiation processes remained speculative. In
keratinocytes, a sustained PLD activation is associated with
diﬀerentiation. It is supposed to provide a prolonged supply of
diacylglycerol resulting from phosphatidic acid hydrolysis and
induce the late activation of certain PKC isoforms [23]. PLD1 is
upregulated during diﬀerentiation of C6 glioma cells and PC12
pheochromocytoma cells [24]. Concerning myogenesis, it is
tempting to infer from the ability of PLD to aﬀect the actin
cytoskeleton, which has been established in endothelial cells
[25] and in ﬁbroblasts [26], that PLD-dependent cytoskeletal
rearrangements might play a pivotal role. Indeed, it has been
demonstrated in cardiomyocytes [27] and in smooth muscle
cells [28] that the status of actin in the cell governs the tran-
scription of muscle-speciﬁc genes. In agreement with this hy-
pothesis, we observed that stimulation of L6 myoblasts by a
myogenic concentration of TPA induced the formation of
stress ﬁber-like actin structures, in a PLD-dependent way as
shown by selective inhibition by 1-butanol. It thus appears that
PLD may be an essential factor of myogenic diﬀerentiation
through its involvement in the reorganization of cytoskeleton.
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that a strong activation of some PKC isoforms by high TPA
concentration induced the mobilization of factors exerting a
blocking eﬀect on the myogenic process, thereby preventing
the triggering of diﬀerentiation insured by transient PLD ac-
tivation. Thus, the TPA-responsive PKCh has been implicated
in inhibiting chick myotube formation by virtue of its ability to
phosphorylate the PKC substrate MARCKS [11]. Further-
more, PKC may induce the inhibition of essential components
of the myogenic machinery. When expressed in mouse C2C12
myoblasts, a constitutively active PKCa phosphorylates and
inactivates myogenin, thus repressing the myogenic program
[29]. In line with this observation, in chick embryo myoblasts
the positive eﬀect of dihydroxy-vitamin D3 on diﬀerentiation
correlates with a decrease in PKC activity and PKCa expres-
sion [30]. Conversely, high TPA concentrations might exert
negative eﬀects by eliminating PKC and thus preventing the
delayed activation of PKC targets essential to the completion
of diﬀerentiation, in addition to PLD. Several PKC-dependent
events exerting a positive inﬂuence on myogenesis have been
reported. For example, RhoA, a well-identiﬁed positive eﬀec-
tor of myogenic diﬀerentiation [3], undergoes PKCa-mediated
activation and translocation in C2C12 myoblasts, and PKC
inhibition or downregulation prevents these eﬀects [31]. In
rhabdomyosarcoma RD cells, it has been shown that the
myogenic response is mediated by PKCa-induced transient
activation of JNK and sustained activation of p38 kinase and
ERKs, PKC inhibition preventing the accumulation of the late
diﬀerentiation marker sarcomeric myosin heavy chain [2]. In
addition, chronic exposure of diﬀerentiated avian skeletal
muscle cells to TPA, that induces a drastic PKC downregu-
lation, results in the loss of expression of muscle-speciﬁc con-
tractile proteins and disassembly of sarcomeric structures,
showing that sustained PKC activity is required for the
maintenance of the diﬀerentiated myocyte phenotype [9].
The present study shows that low concentrations of the
phorbol ester TPA, allowing a sustained increase in PLD ac-
tivity, are able to bring myoblasts to complete diﬀerentiation.
The involvement of PLD in the myogenic response to TPA was
conﬁrmed by the complete blockade of the response in the
presence of a primary alcohol. The PLD pathway thus appears
to play an important role in the myogenic process. The de-
lineation of the mechanism by which PLD might participate in
myogenesis will deserve further investigations.References
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